Secondary prevention of cerebral infarction
نویسندگان
چکیده
منابع مشابه
Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction.
Cilostazol, an antiplatelet drug that increases the cyclic adenosine monophosphate (AMP) levels in platelets via inhibition of cyclic AMP phosphodiesterase, has been used in chronic arterial occlusive disease. The purpose of the present study was to examine the effects of cilostazol on the recurrence of cerebral infarction using a multicenter, randomized, placebo-controlled, double-blind clinic...
متن کاملSecondary Prevention after Myocardial Infarction
Myocardial infarction reflects the most severe form of ischaemic heart disease (IHD) and falls under the increasingly used umbrella term, acute coronary syndrome (ACS). Improvements in the acute management of myocardial infarction have seen deaths due to the condition fall by 31% over the period from 2002 to 2011. Nonetheless, behind this encouraging headline lie some less positive statistics. ...
متن کاملPharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral infarction.
BACKGROUND The antiplatelet agent, cilostazol, is known to reduce the risk of subsequent cerebral infarction. However, the cost effectiveness of such treatment in comparison to aspirin has not been studied. METHODS AND RESULTS A Markov model was developed to calculate the health outcomes and associated costs for 65-year-old patients with cerebral infarction who were treated with 200 mg/day ci...
متن کاملSmoking and myocardial infarction: secondary prevention.
This prospective study examines the question 'Is it too late to stop smoking cigarettes once you have had a myocardial infarction?' One hundred and nineteen cigarette smokers (90 men, 29 women) who survived their first myocardial infarction for one month were followed for five years or until their death if earlier. The age corrected mortality rate of men who continued to smoke cigarettes was 2....
متن کامل[Secondary prevention after a myocardial infarction].
Patients after a myocardial infarction are at increased risk of adverse cardiovascular outcomes. They require aggressive secondary preventive measures to control cardiovascular risk factors, and prescription of some pharmacological agents. Compelling data derived from randomized controlled trials have shown the benefits of aspirin (or clopidogrel), statins, beta-blockers and angiotensin-convert...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Tenri Medical Bulletin
سال: 2016
ISSN: 1344-1817,2187-2244
DOI: 10.12936/tenrikiyo.19-013